To describe the epidemiology and outcomes of individuals with mucormycosis treated with lower dose ABCD, specifically assessing its efficacy, safety, and overall survival rates.
Key Findings:
ABCD was prescribed at 3-6 mg/kg/day, showing effectiveness in treating mucormycosis, with documented 90-day survival rates indicating its potential as a viable treatment option.
Adverse drug reactions (ADRs) were assessed, with severity categorized from grades 1 to 5, highlighting the safety profile of ABCD.
Interpretation:
ABCD appears to be an effective and safer alternative for treating mucormycosis, especially in regions where other formulations are unavailable, warranting further comparative studies.
Limitations:
Retrospective study design may introduce bias, particularly in data collection and patient selection.
Small sample size limits generalizability of findings.
Lack of control group for comparison.
Conclusion:
ABCD is a promising treatment for mucormycosis, offering improved accessibility and affordability, particularly in resource-limited settings, but further studies are needed to confirm these findings.